Clinical

Articles

“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.

Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder

“Our algorithms were extremely accurate in predicting treatment response to both modalities. In fact, they could correctly predict which patient was a responder and which patient was a non-responder about 90% of the time in patients they had never seen before,” said Glenn Werneburg, MD, PhD. 

Study shows machine learning is predicting outcomes in overactive bladder

Videos

“leva can help women successfully do pelvic floor muscle training and experience symptom resolution,” says Samantha Pulliam, MD.

Dr. Pulliam on future research for the leva Pelvic Health System

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Ekene A. Enemchukwu, MD, MPH, discusses the development of β3 agonists for the treatment of overactive bladder.

Beta 3 agonists: A “much-needed alternative” for patients with OAB

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

leva Pelvic Health System shows efficacy for improving symptoms of urinary incontinence

"β3 agonists really provided a new drug class of medications for patients with overactive bladder. Previously, there were no alternatives," says Ekene Enemchukwu, MD, MPH.

Urology Times 50 Innovations Series: β3 agonists for overactive bladder

“In this subgroup analysis of data from the EMPOWUR trial, vibegron was associated with significant reductions in urgency episodes and micturitions compared with placebo in both the OAB dry and wet populations,” said lead author Jeffrey Frankel, MD.

Vibegron equally effective in OAB wet and dry patients

“This is a unique device in that it shows motion-based biofeedback,” says Samantha Pulliam, MD.

Dr. Samantha Pulliam describes the leva Pelvic Health System

At standard stimulation parameters, the Axonics F15 system is expected to function for 15+ years; at lower energy settings, this extends to 20+ years.

New recharge-free sacral neuromodulation system for bladder/bowel dysfunction launches in US

"The biggest improvement in my patients has been the urgency frequency and urgency incontinence, and even some of the patients with irritable bowel," says David W. Law, DO.

OAB and Incontinence